Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

Vor Bio reported that the Phase 3 TELIGAN trial met its 104-week primary endpoint: annualized eGFR decline was -0.6 versus -5.7 mL/min/1.73 m²/year with placebo, a 5.1 difference (p<0.001). Telitacicept was associated with 89% and 81% lower risks of confirmed ≥30% and ≥40% eGFR declines, respectively, and a 60.7% placebo-adjusted reduction in proteinuria. Serious adverse events occurred in 8.2% of treated patients versus 18.2% with placebo; the China-conducted results have not been independently verified by Vor Bio and may not predict outcomes elsewhere.

Analysis

The key value transfer is clinical de-risking of VOR’s ex-Greater-China rights, not near-term China sales: RemeGen controls Chinese development and commercialization, and the release does not quantify VOR’s economics under the collaboration. The unusually strong renal-function signal could help differentiate dual BAFF/APRIL inhibition from established IgAN approaches such as targeted-release budesonide and endothelin-pathway therapies, but it is not head-to-head evidence and does not yet establish a global label or commercial share.

The main discount should remain the evidence bridge. TELIGAN was conducted solely in China, the data are partner-reported and unverified by VOR, and the hard kidney-failure event count is small. The near-zero treated eGFR slope is compelling, but regulators may focus on population generalizability, trial conduct, and whether longer-term outcomes support the surrogate. Injection-site reactions may also constrain persistence despite less frequent dosing. Over 1–3 months, scrutiny of full conference data and VOR’s regulatory plans matters more than the headline; over 6–18 months, global trial execution, regulatory acceptance, and collaboration/supply reliability determine whether this becomes an asset rather than a promising China result. The press release alone does not establish that VOR’s other autoimmune programs benefit clinically.

Key Decisions for Investors

• Treat as a positive catalyst for VOR, but do not extrapolate Chinese approval or revenue to VOR. Before sizing, verify collaboration economics, cash runway, share count, and whether any IgAN development costs fall to VOR.
• For event-driven exposure, consider only a small, risk-defined long after reviewing the complete ASN dataset; avoid paying for assumed global efficacy before regulators and global trials bridge the population gap. No price target is supportable from the supplied information.
• Monitor the next VOR update for global trial/regulatory plans and independent data review, plus discontinuations, serious adverse events, and durability after less-frequent dosing. These are more decision-relevant than the headline p-value.
• Falsify or materially reduce the thesis if additional analysis weakens the eGFR effect, global regulators indicate the China dataset is insufficient, safety or persistence worsens, or VOR discloses economics or funding needs that materially dilute the value of its ex-China rights.